SYNCORE BIOTECHNOLOGY CO.,LTD Financials SynCore Biotechnology Co.,Ltd
Equities
4192
TW0004192000
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.7 TWD | -1.00% |
|
-1.97% | +16.41% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,055 | 2,921 | 4,977 | 3,654 | 2,923 | 1,350 |
| Enterprise Value (EV) 1 | 1,576 | 2,599 | 4,660 | 3,219 | 2,718 | 1,081 |
| P/E ratio | -6.36 x | -6.61 x | -12.2 x | -7.87 x | -15.5 x | -32.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 267 x | 225 x | 373 x | 527 x | 184 x | 66.9 x |
| EV / Revenue | 204 x | 200 x | 349 x | 464 x | 171 x | 53.5 x |
| EV / EBITDA | -6.15 x | -6.31 x | -12 x | -7.08 x | -14.4 x | -29.2 x |
| EV / FCF | -9.16 x | -9.41 x | -22.8 x | -52.9 x | -19 x | -14.6 x |
| FCF Yield | -10.9% | -10.6% | -4.39% | -1.89% | -5.27% | -6.84% |
| Price to Book | 2.91 x | 4.77 x | 8.88 x | 8.25 x | 11.7 x | 3.78 x |
| Nbr of stocks (in thousands) | 22,273 | 26,013 | 28,474 | 30,745 | 30,745 | 35,165 |
| Reference price 2 | 92.27 | 112.3 | 174.8 | 118.8 | 95.07 | 38.40 |
| Announcement Date | 14/03/19 | 06/03/20 | 26/03/21 | 18/03/22 | 06/03/23 | 19/03/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7.706 | 12.97 | 13.34 | 6.939 | 15.86 | 20.2 |
| EBITDA 1 | -256.2 | -412.1 | -388.7 | -454.5 | -189.1 | -36.99 |
| EBIT 1 | -301 | -416.6 | -395.6 | -458.6 | -191.5 | -45.5 |
| Operating Margin | -3,906.36% | -3,212.67% | -2,966.74% | -6,609.3% | -1,207.5% | -225.3% |
| Earnings before Tax (EBT) 1 | -294.1 | -408.6 | -398.9 | -458.6 | -188.7 | -38.17 |
| Net income 1 | -294.1 | -408.6 | -398.9 | -458.6 | -188.7 | -38.17 |
| Net margin | -3,816.86% | -3,151.36% | -2,991.29% | -6,608.98% | -1,189.8% | -189.01% |
| EPS 2 | -14.51 | -16.98 | -14.34 | -15.10 | -6.137 | -1.191 |
| Free Cash Flow 1 | -172.1 | -276.2 | -204.6 | -60.81 | -143.2 | -73.89 |
| FCF margin | -2,232.7% | -2,130.01% | -1,534.13% | -876.33% | -903.05% | -365.84% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 14/03/19 | 06/03/20 | 26/03/21 | 18/03/22 | 06/03/23 | 19/03/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 479 | 322 | 317 | 434 | 205 | 269 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -172 | -276 | -205 | -60.8 | -143 | -73.9 |
| ROE (net income / shareholders' equity) | -41.2% | -62% | -68% | -91.4% | -54.5% | -12.6% |
| ROA (Net income/ Total Assets) | -22.8% | -33.2% | -29.5% | -33% | -19% | -6.98% |
| Assets 1 | 1,290 | 1,231 | 1,353 | 1,391 | 994.1 | 547 |
| Book Value Per Share 2 | 31.70 | 23.50 | 19.70 | 14.40 | 8.100 | 10.20 |
| Cash Flow per Share 2 | 21.20 | 14.90 | 18.90 | 18.00 | 8.750 | 7.530 |
| Capex 1 | 2.99 | 3.55 | 5.12 | 0.29 | 0.14 | 0.42 |
| Capex / Sales | 38.84% | 27.38% | 38.42% | 4.15% | 0.85% | 2.05% |
| Announcement Date | 14/03/19 | 06/03/20 | 26/03/21 | 18/03/22 | 06/03/23 | 19/03/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +16.41% | 48.64M | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -2.30% | 21.28B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B | |
| -28.60% | 7.83B |
- Stock Market
- Equities
- 4192 Stock
- Financials SynCore Biotechnology Co.,Ltd
